Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immunovia AB ( (SE:IMMNOV) ) just unveiled an update.
Immunovia AB, listed on Nasdaq Stockholm under the ticker IMMNOV, specializes in pancreatic cancer diagnostics and works with healthcare providers, experts and patient advocacy groups to make its early detection tests available to individuals at elevated risk. The company views the United States as its largest market opportunity for annual surveillance testing among high‑risk populations.
The company will publish its fourth‑quarter 2025 results on 24 February 2026 and hold an English‑language webcast teleconference the same day, led by CEO Jeff Borcherding. Analysts, investors and media will be able to hear updates on the company’s fourth‑quarter developments and participate in a Q&A session, offering stakeholders fresh insight into Immunovia’s operational progress and commercial trajectory in pancreatic cancer diagnostics.
The most recent analyst rating on (SE:IMMNOV) stock is a Hold with a SEK0.22 price target. To see the full list of analyst forecasts on Immunovia AB stock, see the SE:IMMNOV Stock Forecast page.
More about Immunovia AB
Immunovia AB is a Swedish diagnostic company focused on improving survival rates for pancreatic cancer patients through early detection. The company develops and commercializes simple blood-based tests that detect proteins and antibodies indicating that high‑risk individuals may have developed pancreatic cancer, targeting an estimated 1.8 million such people in the U.S. market.
YTD Price Performance: -25.55%
Average Trading Volume: 6,560,629
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK118.9M
For detailed information about IMMNOV stock, go to TipRanks’ Stock Analysis page.